Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Chun Loo GanShaan DudaniJ Connor WellsFrede DonskovSumanta Kumar PalNazli DizmanNityam RathiBenoit BeuselinckFlora YanAly-Khan A LalaniAaron Richard HansenBernadett SzabadosGuillermo de VelascoBen TranJae Lyun LeeUlka N VaishampayanGeorg A BjarnasonMathushan SubasriToni K ChoueiriDaniel Y C HengPublished in: Cancer medicine (2021)
The ORR and TTF of cabozantinib were maintained from the 1L to 4L settings. Dose reductions due to toxicity were associated with improved TTF and OS. Cabozantinib has clinical activity after 1L Immuno-oncology combination agents.